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1. Introduction 
People with severe mental illness have an excess burden of physical comorbidity and 
mortality, especially due to cardiovascular illness, compared to persons without psychiatric 
disorders. Individuals with schizophrenia and bipolar disorder have an increased risk for 
obesity, type 2 diabetes, and other cardiometabolic risk factors but they usually receive 
inconsistent and insufficient physical monitoring and management. There is a wide array of 
variables that may potentially contribute to the increased comorbidity and mortality rates 
associated with major mental disorders and this is partly related to lifestyle factors such as 
poor diet, lack of exercise and smoking.  
A final important source of cardiometabolic risk in major mental disorders is treatment itself 
although before the introduction of the antipsychotic drugs it was acknowledged that 
patients with schizophrenia and bipolar disorder may be at a higher risk of abnormal 
glucose metabolism and metabolic disorders compared to general population. The reasons 
for this difference may include an inherent increased risk of diabetes associated with the 
illness itself and an increased metabolic risk related to behaviors having a negative impact 
on health.  
Although the main aim of the treatment of severe mental illness is to control psychotic 
symptoms and enable patients to function as normally as possible it is really important to 
considerer in choosing a treatment the impact on physical as well as mental health. The 
safety and tolerability of psychotropic drugs are especially important because of the 
chronicity of the illnesses being treated, the need for long-term therapy and the poor insight 
and motivation of many of the patients. The occurrence of side effects determines not only a 
reduction of the physical health of patients as a whole but also a reduction of compliance 
and we know that sub-optimal adherence to psychotropic medication, in particular 
antipsychotics, greatly increases the risk of relapse and rehospitalisation. 
About antipsychotics, between-drug differences in efficacy are relatively modest for the 
atypicals, or between atypicals and conventionals, while differences in safety and 
tolerability are larger and more clinically relevant. The lower risk of extrapyramidal 
symptoms and tardive dyskinesia with atypical antipsychotics has allowed a greater focus 
on other physical health risks associated with these treatment. Antipsychotic drugs have 
side effects such as weight gain, lipid abnormalities and disturbance of glucose regulation 
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that increase the risk of the metabolic syndrome, a recognized cluster of features 
(hypertension, central obesity, glucose intolerance ⁄ insulin resistance and dyslipidaemia) 
that is predictive of both type-2 diabetes and atherosclerotic vascular disease.  
About the side effect of antipsychotics, in the past few years, particular attention has been 
paid to the ability of these drugs to prolong the corrected QT (QTc) interval, which may 
result in torsades de pointes and sudden cardiac death. Other factors that could lead to QTc 
lengthening in psychotic patients are the presence of abnormalities in glucose metabolism 
and comorbid cardiovascular diseases witch are increased in patients treated with 
antipsychotics. 
These matters emphasize that cardiovascular safety of antipsychotic drugs is of paramount 
importance because patients diagnosed with schizophrenia, schizoaffective disorder, or 
bipolar disorder are at high risk to begin with. 
All reviews of the association between psychotic illness, metabolic syndrome and 
antipsychotic medication point to the need for routine physical health screening of patients 
prescribed antipsychotic drugs, whatever the indication for such treatment. The 
maintenance of physical health is an important factor in the successful global management 
of these patients. For these reasons there is clearly a need for clinicians to employ multiple 
strategies to minimize metabolic risk in schizophrenia patients, including using 
metabolically more neutral medications, promoting healthier lifestyle habits, developing 
expertise in switching antipsychotics for metabolic reasons and, most importantly, 
practicing good preventive care through regular monitoring of metabolic parameters. 
In recent years the importance of physical health in people with psychotic illness treated 
with antipsychotics has led to monitoring recommendations cosponsored by different 
associations (endocrinology, cardiology and psychiatry) in United States and in Europe 
although general health care needs in psychiatric population are commonly neglected and 
psychiatrists mainly focus on efficacy of treatment of psychotic symptoms. 
The aim of this chapter is to evaluate the clinical importance of cardiometabolic risk factors 
among persons with mental disorders, addressing the contribution of antipsychotic 
medications to increased cardiometabolic risk, and suggesting monitoring strategies for 
modifiable risk factors relevant to the treatment of serious mental illness. 
A Medline search was performed to examine published data from 1990 through June 2011. 
The search included the following keywords: ‘diabetes’, ‘weight gain’, ‘weight 
management’, ‘dyslipidaemia’, ‘metabolic syndrome’, ‘QTc interval’, ‘metabolic and 
cardiovascular risk’, and were used interchangeably and were also combined in the search 
together with ‘schizophrenia’, ‘bipolar disorder’, ‘severe mental illness’ and ‘antipsychotic 
drugs’. 
Papers were included if they were published in English, with a diagnosis of schizophrenia 
or bipolar disorder and treatment with antipsychotic medication. 
Studies were also included if the focus was on monitoring and improvement in metabolic 
profile through the application of different strategies, such as psychoeducational (exercise 
and dietary) interventions or switching patients to less metabolically offending 
medications. 
2. The burden of cardiometabolic illness 
Individuals with major mental disorder, including schizophrenia, bipolar disorder and 
schizoaffective disorder, are prone to many different physical health problems (De Hert et 
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al., 2011). While these diseases are also prevalent in the general population, their impact on 
individuals with major mental disorder is significantly greater (Maj, 2009). 
Subjects with major mental disorder tend to have more illnesses and a shorter lifespan than 
the general population, having a life expectancy that is approximately 20% shorter  
(Newman & Bland, 1991). Recently, a multistate study in U.S, supported by the Center for 
Mental Health Services in collaboration with the National Association of State Mental 
Health Program Directors, found that patients with serious mental illness lost an average of 
25 years of potential life expectancy compared to current life expectancy in the general 
population. (Table 1) (Colton & Manderscheid, 2006).  
 
Year Arizona Missouri Oklahoma
Rhode 
Island 
Texas Utah Virginia 
1997  26.3 25.1  28.5   
1998  27.3 25.1  28.8 29.3 15.5 
1999 32.2 26.8 26.3  29.3 26.9 14.0 
2000 31.8 27.9  24.9   13.5 
Table 1. Mean Number of Years of Potential Life Lost (YPLL) per Public Mental Health 
Client Who Died During a Year in Which a Service Was Received (modified from Colton & 
Manderscheid, 2006) 
 
Modifiable Risk Factors 
Estimated Prevalence & Relative Risk (RR) 
Schizophrenia Bipolar Disorder 
Obesity 45–55%, RR: 1.5-2 21–49%, RR: 1-2 
Smoking 50–80%, RR: 2-3 54–68%, RR: 2-3 
Diabetes 10%–15%, RR: 2 8–17%, RR: 1.5-2
Hypertension 19–58%, RR: 2-3 35-61%, RR: 2-3
Dyslipidemia 25-69%, RR: ≤5 23-38%, RR: ≤3 
Metabolic Syndrome 37-63%, RR: 2-3 30-49% RR: 1.5-2 
Table 2. Estimated prevalence and relative risk of modifiable cardiovascular disease risk 
factors in patients with schizophrenia and bipolar disorder compared to the general 
population (modified from Correl, 2007) 
This mortality gap has been noted in different study (Saha et al., 2007; Robson & Gray, 2007) 
even in countries where the quality of the health care system is generally acknowledged to 
be good (Osby et al., 2000). The excess mortality was attributable to physical illness (Saha et 
al., 2007; Robson & Gray, 2007), with cardiovascular disease (CVD) being the major 
contributor (Colton & Manderscheid, 2006). A recent cohort study of primary care patients 
in the UK has confirmed the increased prevalence of CVD associated with severe mental 
illness (Osborn, 2007) and different authors agree that cardiovascular illness may partly 
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explain why patients with schizophrenia die at least 10 years earlier than the general 
population (Heald et al., 2010; De Hert et al., 2011).  
Risk factors for cardiovascular morbidity and mortality in the general population include 
those that are inherently non-modifiable (gender, age, family history) and those that are 
modifiable through behavioural changes and improved care (Heald et al., 2010). The 
differential risk for morbidity and mortality from CVD in patients with schizophrenia and 
bipolar disorder compared to the general population can be explained by a 1–5-fold (Tab. 2) 
relative risk for modifiable risk factors for CVD (Correll, 2007). These risk factors include 
smoking (Hennekens et al., 2005; S. Davidson et al., 2001; Goff et al., 2005; Herran et al., 
2004; Ucok et al., 2004), obesity (Hennekens et al., 2005; Fagiolini et al., 2005), diabetes 
(Fagiolini et al., 2005; Goff et al., 2005; Kilbourne et al., 2004), arterial hypertension 
(Hennekens et al., 2005; Fagiolini et al., 2005; Goff et al., 2005; ), dyslipidemia (Hennekens et 
al., 2005; Fagiolini et al., 2005; Nasrallah et al., 2006) and metabolic syndrome (Meyer et al., 
2005; McEvoy et al., 2005; Cohn et al., 2004; Kato et al., 2004; Heiskanen et al., 2003; 
Birkenaes et al., 2007; Yumru et al., 2007). 
2.1 Metabolic syndrome 
With regard to cardiovascular risk in persons with severe mental illness, of most concern is 
the development of metabolic syndrome (Casey, 2005; Angst et al., 2002). It has also been 
found in 37% of patients with long-term schizophrenia (Heiskanen et al., 2003) compared 
with 24% in the general population and after adjusting for age, these data suggest that 
persons with schizophrenia have double the incidence of the metabolic syndrome compared 
with the general population (Ford et al., 2002). Metabolic syndrome rates in patients with 
bipolar disorder and schizoaffective disorder have been reported to be 30-49% (Fagiolini et 
al., 2005; Pacholczyk et al., 2008; De Hert et al., 2011) and 42% (Basu et al., 2004), 
respectively. 
With the metabolic syndrome, individuals have approximately a 5-6 fold increased risk of 
developing diabetes and a 3-6 fold increased risk of mortality due to coronary heart disease 
(Grundy, 2006; Hanson et al., 2002; Laaksonen et al., 2002, Fagiolini et al., 2005; Li & Ford, 
2006; Bhargava, 2003; Grundy, 2006; Pacholczyk et al., 2008). In a study of 3606 general 
population subjects (Isomaa et al., 2001) over a median follow-up of 6.9 years, the presence 
of the syndrome was associated with significantly higher all-cause mortality (18.0% versus 
4.6%; p < 0.001) and cardiovascular mortality (12.0% versus 2.2%; p < 0.001). 
Despite several definitions of the metabolic syndrome have been proposed over the years 
(Tab. 3), there is agreement that the major characteristics of the syndrome include central 
obesity, hypertension, dyslipidemia, glucose intolerance or insulin resistance (Li and Ford, 
2006; Grundy et al., 2005; De Hert et al., 2011).  
Alarmingly, the metabolic syndrome risk appears to be relatively highest in younger 
patients, which is likely to be responsible for the dramatically reduced life expectancy 
(Colton and Manderscheid, 2006), with an increased risk over the course of the illness 
(Fig.1). In a cross-sectional study (Graph.1) metabolic syndrome rate, using NCEP ATP III 
definition, for first-episode patients (<1.5 years) was 17%; for recent onset patients (1.5– 10 
years) it was 21.5%; for subchronic patients (10–20 years) it was 34.9%; and for chronic 
patients (>20 years) it was 36.7% (De Hert M et al., 2006).  
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Criteria NCEP ATP III 
(2001)
NCEP ATP III A 
(2004)
IDF (2005) IDF & 
AHA/NHLBI (2009) 
Required factor None
but any 3 or more 
of the following
None
but any 3 or more 
of the following
Central obesity
plus any 2 of the 
following
None 
but any 3 or more 
of the following 
Additional 
factors 
Obesity waist 
circumference 
≥102 cm (men)  
≥88 cm (women) 
waist 
circumference 
≥102 cm (men)  
≥88 cm (women) 
Elevated waist 
circumference and 
country-specific 
definitions as 
defined by the IDF 
and AHA/ NHLBI 
until more data are 
available 
Triglycerides ≥150 mg/dL (≥1.7 
mmol/L) or  
on elevated 
triglycerides Rx 
≥150 mg/dL (≥1.7 
mmol/L) or  
on elevated 
triglycerides Rx 
≥150 mg/dL (≥1.7 
mmol/L) or 
on lipid abnorma- 
lity Rx 
≥150 mg/dL (≥1.7 
mmol/L) (Rx for 
ele- vated 
triglycerides is 
an alternate 
indicator) 
HDL - 
cholesterol 
<40 mg/dL (<1.03 
mmol/L)(men) 
<50 mg/dL (<1.29 
mmol/L) 
(women) or on 
reduced HDL- 
cholesterol Rx 
<40 mg/dL (<1.03 
mmol/L)(men) 
<50 mg/dL (<1.29 
mmol/L) 
(women) or on 
reduced HDL- 
cholesterol Rx 
<40 mg/dL (<1.03 
mmol/L)(men)  
<50 mg/dL (<1.29 
mmol/L) (women) 
or  
on lipid 
abnormality Rx 
<40 mg/dL (<1.0 
mmol/L)(men) 
<50 mg/dL (<1.3 
mmol/L) 
(women) (Rx for 
reduced HDL-
cholesterol  
is an alternate 
indicator) 
Blood pressure ≥130/85 mm Hg 
or on  
hypertension Rx 
≥130/85 mm Hg 
or on  
hypertension Rx 
≥130/85 mmHg or 
on 
antihypertensive 
Rx 
≥130/85 mm Hg 
(antihypertensive 
Rx in a patient 
with a history  
of hypertension  
is an alternate 
indicator) 
Glucose ≥110 mg/dL (≥6.1 
mmol/L) 
(includes 
diabetes 
mellitus) or  
on elevated  
glucose Rx
≥100 mg/dL) (≥5.6 
mmol/L) 
(includes 
diabetes 
mellitus) or  
on elevated  
glucose Rx
≥100 mg/dL (≥5.6 
mmol/L) or 
previously 
diagnosed type 2 
diabetes mellitus 
≥100 mg/dL (≥5.6 
mmol/L) (Rx of 
elevated glucose  
is an alternate 
indicator) 
NCEP ATP III: Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults 
(Adult Treatment Panel III)  
IDF: International Diabetes Federation 
AHA/NHLBI: American Heart Association/National Heart, Lung, and Blood Institute 
Table 3. Definitions of the metabolic syndrome (modified from De Hert et al., 2011) 
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Graphic 1. Metabolic syndrome prevalence over the disease course of schizophrenia 
(modified from De Hert M et al., 2006) 
2.2 Diabetes 
Currently, 70% of people with diabetes live in developing countries, and while diabetes is 
increasing across the world, its greatest increase will be in these countries (De Hert et al., 
2011). By 2030 more than 80% of people with diabetes mellitus will live in developing 
countries (Whiting et al., 2010). Persons with diabetes have an increased risk of CVD, and 
CVD is the cause of death in 70% to 80% of these individuals (Sicree et al., 2003). Evidence 
suggests that the prevalence of diabetes in people with schizophrenia as well as in people 
with bipolar disorder and schizoaffective disorder is 2-3 fold higher compared with the 
general population (Bushe and Holt, 2004;). 
The reason for the increased risk of diabetes mellitus in patients with major mental disorder 
is multifactorial and includes genetic and lifestyle factors as well as disease and treatment 
specific effects (Fig. 1). An increase in well-established diabetes risk factors in these patients 
partially accounts for much of the increased risk (De Hert et al., 2011). However, additional 
factors (disease, treatment) are important as well, and research suggests that, compared to 
the general population (De Hert M et al., 2006), the prevalence of diabetes in schizophrenia 
patients is 4 to 5 times higher in different age groups (Graph. 2). 
In the general population two important factors that contribute to the development of 
diabetes are insulin resistance and obesity (Fig. 1). The link between obesity and diabetes is 
well established (Heald, 2010). A 10 year follow-up study has shown that people with a 
body mass index (BMI) of ≥35 are approximately 20 times more likely to develop diabetes 
than age and gender-matched subjects with a BMI of <25 (Field et al., 2001).  
The reasons of an higher prevalence of diabetes in schizophrenia patients over the course of 
the illness is probably an effect of an increased prevalence of obesity, often attributed to 
antipsychotic treatment (Montejo, 2010; Mulnier et al., 2006).  
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Graphic 2. Prevalence of diabetes in schizophrenia patients over the disease course 
compared to the general population (modified from De Hert M et al., 2006) 
 
 
Fig. 1. Factors influencing the risk of diabetes among patients with schizophrenia (M. Smith 
et al., 2008) 
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2.3 Obesity 
Obesity is becoming a significant and growing health crisis, affecting both developed and 
developing countries (Haslam & James, 2005; De Hert et al., 2011). People with obesity have 
shorter life spans and are at increased risk for a number of general medical conditions, 
including type 2 diabetes mellitus, diabetes mellitus (relative risk, RR >3), cardiovascular 
disease, CVD (RR >2-3), dyslipidemia (RR >3), hypertension (RR >2-3), respiratory 
difficulties (RR >3), reproductive hormone abnormalities (RR >1-2) and certain cancers (e.g., 
colon) (RR >1-2) (McElroy, 2009; Bray & Wilson, 2008). Levels of obesity are higher in those 
with schizophrenia and depression, as well as the mortality from obesity-related conditions 
such as coronary heart disease (Allison et al., 2009). Increasing evidence suggests that 
persons with major mental disorder are, compared to the general population, at increased 
risk for overweight and obesity (Graph. 3) (Allison et al., 1999; Dickerson et al, 2006).  
 
 
Graphic 3. BMI distributions in schizophrenia patients and the general population (Allison 
et al., 1999) 
This excess prevalence, however, has not been reported consistently in the past. Despite 
some early reports of obesity in the pre-antipsychotic era (Kraepelin, 1919), classical 
descriptions of schizophrenia refer to a thin ‘neurasthenic’ body habitus and many people 
with first-episode psychosis are not overweight (Green et al., 2006; Lieberman et al., 2003). 
Some recent studies show that drug-naive schizophrenia does not present with higher rates 
of obesity and metabolic problems than a normal population with comparable lifestyle 
(Padmavati et al., 2010; Verma et al., 2009). Taken together these findings suggest that other 
factors such as treatment or lifestyle factors may be play an important role in the 
development of weight gain in these patients over the course of the illness.  
2.4 Dyslipidemia 
Any increase in cholesterol levels has significant health implications, as a 10% increase in 
cholesterol levels is associated with a 20% to 30% increase in the risk of coronary heart 
disease (LaRosa et al., 1990). 
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Elevated fasting triglycerides (TG) are a direct result of insulin resistance, because insulin-
dependent lipases in fat cells are normally inhibited by insulin (Stahl et al., 2009). As insulin 
resistance worsens, inappropriately high levels of lipolysis lead to the release of excess 
amounts of free fatty acids that are hepatically transformed into TG (D.A. Smith, 2007). 
Elevated fasting TG levels thus become a sensitive marker of insulin resistance, with fasting 
TG to high density lipoprotein (HDL) ratios (TG : HDL) ≥ 3.0 performing better than fasting 
glucose in predicting insulin resistance (McLaughlin et al., 2003). 
While fasting TG values provide important information on insulin resistance, fasting TG 
and especially non-fasting TG, also correlate with cardiovascular risk. recent studies indicate 
that nonfasting TG may be more important for the development of atherosclerotic arterial 
injury and subsequent CV risk.  
The basis of this assertion lies in the concept that arterial injury may occur primarily during 
the postprandial period, when TG-rich particles are at their highest level and penetrate 
arterial intimal cells (Eberly et al., 2003). Results of a large (n = 13 981) European trial with 
extensive follow-up (mean 26 years), indicate a significant correlation between non-fasting 
TG levels and risk of major cardiovascular events (Nordestgaard et al., 2007). 
3. Treatments exacerbate cardiometabolic risk factors 
In addition to increased vulnerability to developing physical health problems, it has also 
been reported that side-effects of antipsychotic drugs have been linked to other physical 
health conditions such as weight gain, diabetes, and dyslipidaemia (Bobes et al., 2010). 
Equally, antidepressants (AD) such as paroxetine (Fava et al., 2006), and mood stabilizers, 
such as lithium and valproate (Bowden et al., 2000), have been associated with weight 
gain. 
While first-generation antipsychotics (FGAs) might also lead to weight gain, especially the 
less frequently used low-potency FGAs, certain second-generation antipsychotics (SGAs) are 
now known to induce much greater weight gain (Graph. 4) and cardiometabolic changes in 
certain patients (Leucht et al., 2009).  
 
 
Graphic 4. Effect of second generation versus first-generation antipsychotic on weight gain 
(modified from Leucht et al., 2009) 
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Of these agents, clozapine and olanzapine are generally associated with the greatest impact 
on body weight during both shorter- and longer-term (Leucht et al., 2009) therapy. Data 
suggest that risperidone has an intermediate effect on weight in the short term, and 
quetiapine appears to have a short-term weight gain potential similar to that of risperidone 
(Leucht et al., 2009). By comparison, the newer antipsychotic agents, aripiprazole and 
ziprasidone, are associated with minimal weight gain (Leucht et al., 2009).  
The paliperidone extended release, the active metabolite of risperidone, has the same weight 
gain profile as its parent drug (M. Davidson et al., 2007).  
No agent, however, should be considered as truly weight-neutral, as the proportion of 
individuals experiencing ≥7% weight gain is greater with any SGAs than with placebo 
(Citrome, 2007), and all antipsychotics have been found to cause significant weight gain in 
antipsychotics naïve or first-episode patients (Alvarez-Jiménez et al., 2008; Correll et al., 
2009; Saddichha et al., 2007) (Tab. 4).  
Another important issue is that the weight gain during treatment with antipsychotics occurs 
in the first weeks (4-6), therefore careful monitoring is necessary to start from the beginning 
of treatment (Jones et al., 2001; Kinon et al., 2005). 
 
Drug Weight gain 
Glucose 
effects 
Lipid effects 
QTc 
prolungation 
Clozapine +++ +++ +++ 0 
Olanzapine +++ +++ +++ 0 
Risperidone ++ ++ ++ + 
Quetiapine ++ ++ ++ 0 
Amisulpride + + + 0 
Aripiprazole 0 0 0 0 
Ziprasidone 0 0 0 ++ 
Paliperidone ++ 0 0 0 
Sertindole ++ ++ ++ ++ 
Zotepine +++ +++ +++ + 
Haloperidol + 0 0 + (IV) 
0 = no risk or rarely causes side effects at therapeutic dose, + = mild or occasionally causes side effects 
at therapeutic dose, ++ = sometimes causes side effects at therapeutic dose, and +++ = frequently 
causes side effects at therapeutic dose. 
Table 4. Cardiometabolic side effects of antipsychotics (modified from Marder et al., 2004) 
Although the mechanisms underlying weight gain are still unknown after initiation of 
antipsychotic treatment, a strong increase of appetite is combined with immediate 
substantial weight gain (Theisen et al., 2003; Gebhardt et al., 2007). The level of H1 
antagonism associated with different antipsychotic medications is hypothesized to modulate 
feeding behavior (increased appetite and decreased sensation of satiety), based on the 
significant association of weight gain and the binding affinity for this receptor. 
Antipsychotics with minimal affinity for H1 receptors, such as aripiprazole, ziprasidone, 
and haloperidol, are associated with limited weight gain, while antipsychotics with a high 
affinity for H1 receptors, such as clozapine, olanzapine, thioridazine, and chlorpromazine, 
are associated with clinically significant increases in weight (Newcomer, 2005).  
Serotonin 2C receptors have been another area of focus, based on data derived from mice 
with the 5HT2C gene “knocked out” (Stahl et al., 2009). The combined blockade of H1 and 
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5HT2C receptors has been especially associated with weight gain – sometimes profound – 
and could explain why atypical antipsychotics such as olanzapine and clozapine, which 
have high 5HT2C as well as H1 affinities, might have greater weight gain liabilities than an 
agent such as chlorpromazine, which lacks appreciable 5HT2C effects, even though it has 
H1 antagonist properties (Cutler et al., 2008; Kroeze et al., 2003). 
The high interindividual variability in medication-induced weight gain suggests that genetic 
factors influence the risk to gain weight (Holt and Peveler, 2009).  
Studies of genetic predictors of weight gain under antipsychotic therapy have mainly but 
not exclusively (Vehof et al., 2010) focused on HTR2C (Mulder et al., 2007; Opgen-Rhein et 
al., 2010) and LEPR (Opgen-Rhein et al., 2010; Gregoor et al., 2009) gene polymorphisms. 
Second generation antipsychotics seem also to have a stronger diabetogenic risk than first 
generation antipsychicotics (Scheen and De Hert, 2007; Okumura et al., 2010; Citrome et al., 
2007), the risk being 1.3 fold higher in people with schizophrenia taking SGAs compared 
with those receiving FGAs (M. Smith et al., 2008). However, the risk of diabetes-related 
adverse events differs between SGAs. specifically olanzapine (Ramaswamy et al., 2006; 
Yood et al., 2008; Koller & Doraiswamy, 2002; Starrenburg & Bogers, 2009) and clozapine 
(Yood et al., 2008; Starrenburg &Bogers, 2009; Koller et al., 2001) and, to a lesser extent, 
quetiapina (Koller et al., 2004) and risperidone (Koller et al., 2003), are associated with an 
increased risk of diabetes (Strassnig et al., 2003) in people who have schizophrenia or 
bipolar disorder (Guo et al., 2007; Guo et al., 2006). A recent large-scale 
pharmacoepidemiologic study (including 345.937 patients) found low to moderate, but 
significantly increased rates of incident DM compared with the general population for 
clozapine (RR=1.45), olanzapine (RR=1.29) and risperidone (RR=1.23). Rates increased two 
or more times with ziprasidone and sertindole. Aripiprazole, amisulpride and quetiapina 
did not have a significantly increased rate (Kessing et al., 2010). 
Other psychotropic drugs such as antidepressants may also increase the risk of diabetes 
mellitus, probably partly due to side effects such as sedation, increased appetite, and weight 
gain (Sussman et al., 2001; L.C. Brown et al., 2008). Given the heterogeneity and small 
sample sizes of the few currently available studies, it is unclear whether or not specific 
antidepressants themselves may increase the risk of diabetes mellitus. Nevertheless, it seems 
that an increased risk of diabetes is associated with the concurrent use of tricyclic 
antidepressants and serotonin reuptake inhibitors (SSRIs) (OR=1.89) (L.C. Brown et al., 
2008), the long-term use of both tricyclic antidepressants (incidence rate ratio, IRR=1.77) and 
SSRIs (IRR=2.06) in at least moderate daily doses (Andersohn et al., 2009), as well as the use 
of antidepressant medication in high-risk patients (Rubi net al., 2008). Furthermore, 
although understudied, certain mood stabilizers, especially valproate, have been associated 
with an elevated risk for the development of insulin resistance (Verrotti et al., 2009; 
Pylvänen et al., 2006), conferring a risk for diabetes mellitus, which is possibly related to 
weight gain (Masuccio et al., 2010), and/or fatty liver infiltration (Luef et al., 2004), but also 
to valproate itself (Pylvänen et al., 2002). 
Additionally to weight gain and diabetes, some SGAs cause hypertriglyceridaemia, which is 
an independent risk factor of coronary arteriosclerosis (Tschoner et al., 2007). A prospective 
study comparing the effects of the SGAs clozapine, olanzapine, risperidone and the FGA 
sulpiride on glucose and lipid metabolism in first-episode schizophrenia at baseline and 8 
weeks after inclusion showed that besides higher C-peptide, fasting insulin and insulin 
resistance index (IRI), cholesterol and triglyceride levels were significantly increased in the 
clozapine and olanzapine groups (Wu et al., 2006). Because of these results the authors 
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recommend that baseline and 6-month monitoring of fasting blood glucose, fasting 
cholesterol and triglyceride levels should be obtained in routine clinical practice with all 
antipsychotics to monitor the risk for development of hyperglycaemia and 
hypercholesterolaemia. Another study described a negative effect of olanzapine 
administration on total cholesterol and triglycerides, whereas favourable metabolic effects 
were observed in ziprasidone-treated patients with regard to total cholesterol, LDL and 
HDL (R.R. Brown & Estoup, 2005). These results were confirmed in different studies 
(Lieberman et al., 2005; Rettenbacher et al., 2006 ) and the authors suggest ziprasidone as a 
favourable alternative treatment for already overweight patients. 
In the assessment of cardiometabolic risk, in recent years, particular attention has been paid 
to the ability of psychotropic drugs to prolong the corrected QT (QTc) interval, which may 
result in torsades de pointes and sudden cardiac death (Glassman, 2005; Zareba, 2007). An 
increasing number of psychotropic drugs, are known to delay cardiac repolarization and to 
induce torsade de pointes.  Antipsychotic drugs have a dose-dependent effect on the 
myocardial repolarization by inhibiting the delayed potassium rectifier current (IKr) (Yap & 
Camm, 2003). There is a consensus that QTc values >500 msec, or an absolute increase of 60 
msec compared with drug-free baseline, puts a patient at significant risk of torsade de 
pointes, ventricular fibrillation and sudden cardiac death (Haddad and Sharma, 2007; Pies, 
2001; Elbe & Savage, 2010). Most antipsychotics and some antidepressants may be 
associated with QTc prolongation (Glassman, 2005). Patients using AP have higher rates of 
cardiac arrest or ventricular arrhythmias than controls, with ratios ranging from 1.7 to 5.3 
(Ray et al., 2001; Hennessy et al., 2002; Reilly et al., 2002). Antipsychotics associated with a 
greater risk of QTc prolongation include pimozide, thioridazine and mesoridazine among 
the FGAs  (Vieweg, 2002; Reilly et al., 2002) and sertindole and ziprasidone among the SGAs 
(Thomas et al., 2010). However, the largest randomized study to date (n=18,154) did not find 
a statistically significant difference in the risk of sudden cardiac death between ziprasidone 
and olanzapine treated patients with schizophrenia (Strom et al., 2011). 
3.1 The time of monitoring 
The maintenance of physical health is an important factor in the successful global 
management of schizophrenia patients. Research studies have continued to draw attention 
to monitoring the physical health of patients with schizophrenia in order to successfully 
enhance these individuals’ quality of life (Nasrallah, 2005). In the past decades physical 
health monitoring of patients with severe mental disorder looked for the extrapyramidal 
symptoms and tardive dyskinesia often associated with conventional antipsychotics. 
Atypical antipsychotics were developed to overcome extrapyramidal side effects associated 
with the use of typical antipsychotics at clinically effective doses, and this has led to 
widespread use since their introduction over a decade ago (Balf et al., 2008). Despite these 
benefits, the use of second generation antipsychotics has also been associated with reports of 
dramatic weight gain, diabetes and atherogenic lipid profiles (Newcomer et al., 2002).  
Over recent years, both national and international groups have developed screening and 
monitoring guidelines (ADA, 2004; De Hert et al., 2009). These guidelines  are based on the 
principle that it is particularly important to establish baseline CVD risk at initial 
presentation so that any subsequent change during treatment can be monitored. The 
medical history and examination should therefore include: history of previous CVD, 
diabetes or other related disease; family history of premature CVD, diabetes or other related 
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disease; smoking habit; weight and height in order to calculate body mass index (BMI) and 
waist circumference; fasting blood glucose; fasting blood lipids: total cholesterol, 
triglycerides, LDLcholesterol (by calculation) and HDL-C; blood pressure (measured twice 
and average taken), heart rate, heart and lung auscultation, foot pulses; ECG (De Hert et al., 
2009). 
 
 Baseline Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 
Week 
12 
History of previous 
CVD or other 
related disease 
X        
Smoking habit X        
Weight X X X X X X X X 
Heigh X        
Waist circumference X X       
Fasting blood 
glucose 
X      X X 
Total cholesterol X      X X 
Triglycerides X      X X 
LDL-C X      X X 
HDL-C X      X X 
Blood pressure X        
ECG X  X      
Table 5. Screening and monitoring of cardiovascular disease risk factors (modified from De 
Hert et al., 2009). 
It is recommended that measurements should be taken at the initial presentation and before 
the first prescription of antipsychotic medication (Tab. 5). The frequency of testing will 
depend on the patient’s medical history and the prevalence of baseline risk factors. For 
patients with normal baseline tests, it is recommended that biochemical measurements are 
repeated at 6 weeks and 12 weeks after initiation of treatment and at least annually 
thereafter. The frequency of testing will depend on the presence of risk factors and detected 
abnormalities. During the initial phase of treatment, it is important to measure weight 
weekly to identify those individuals who gain weight rapidly with psychotropic treatment. 
In patients with diabetes, an assessment of glycaemia control by HbA1c should be made 
regularly (approximately every 3 months). 
The huge amount of  data on cardiometabolic side effects of  antipsychotics have shifted 
over the years  the attention of the clinicians to a greater perception of cardiometabolic 
diseases in patient with severe mental illness (Fig. 2) although still several studies indicate 
that mentally ill patients receive substandard care regarding routine metabolic monitoring 
(Haupt et al., 2009).  
Since the publication of monitoring guidelines in 2004 (ADA 2004) the following 
recommendations have been generally accepted as the standard of care: assessment of CVD 
risk factors and all five components of the metabolic syndrome (ie, weight and waist 
circumference, blood pressure, and fasting glucose and lipids) prior to antipsychotic 
initiation; weight assessments at each visit (or monthly for the first 3 months and then 
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quarterly); and assessment of all components of the metabolic syndrome at 3 months and 
annually. However a retrospective study which evaluated plasma lipid and glucose testing 
rates in patients receiving second-generation antipsychotics before and after guidelines were 
published revealed monitoring for plasma lipids and glucose in this population remains low 
(Haupt et al., 2009).  
Reasons are complex and involve patient nonadherence with medical appointments and 
interventions, suboptimal monitoring and management behaviors of mental and medical 
health care providers, and systems issues of fragmented care and poor access to care. 
 
 
 
 
 
 
 
Fig. 2. Shift in risk perception of antipsychotics 
3.2 Practical issue to reduce cardiometabolic risk 
Given the increased incidence of CVD mortality in people with schizophrenia and bipolar 
disorder, efforts should be made to lower the modifiable risk factors in this population. A 
reduction in the prevalence of metabolic syndrome is an important target to improve the 
physical health of patients with severe mental illness (Heald, 2010). If the patient has central 
obesity, hypertensive blood pressure (≥130/85 mm Hg), pre-diabetes (fasting plasma 
glucose =100-125 mg/dL or hemoglobin A1C =5.7-6.4%) or DM (fasting plasma glucose 
≥126 mg/dL or hemoglobin A1C >6.4%), or marked dyslipidemia (total cholesterol >350 
mg/dL; LDLcholesterol >160 mg/dL; triglycerides >300 mg/dL), he/she should be referred 
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to primary care provider to treat these conditions, unless simple healthy lifestyle guidance 
or behavioural adjustment and/or switching to a lower cardiometabolic risk medication can 
address these medical conditions adequately (De Hert et al., 2009).  
Non-pharmacological interventions, incorporating dietary and physical activity 
modifications, demonstrated promise in terms of preventing weight gain in schizophrenia 
(De Nayer et al., 2005; Sáiz Ruiz et al., 2008; Buckley et al., 2005; Haupt et al., 2009; Vreeland, 
2007; Faulkner et al., 2007; Alvarez-Jiménez et al., 2008). The impact on one’s overall health, 
even with simple life style changes, is considerable. A healthy diet, regular physical activity 
and quitting smoking are the key components of lowering the prevalence and impact of 
modifiable risk factors. However, if lifestyle interventions do not succeed, medication, 
including statins, anti-hypertensive therapy or antidiabetic agents, may be indicated. These 
drugs should be prescribed and managed as for the general population and are generally 
well tolerated (Cormac, 2009; Laurent & Simons, 2009). Moreover, pharmacologic treatments 
added to reduce antipsychotic-related weight can be tried. To date, most evidence exists for 
metformin (500 to 1000 mg bid with meals) or topiramate (50-200 mg in divided doses) 
(Maayan & Correll, 2010). 
If these strategies fail, the clinician should consider switching from a medication with a 
higher weight-gain liability to one with a lower weight gain liability. Ziprasidone and 
perphenazine treatments in the CATIE trial (Lieberman et al., 2005) were associated with 
mean weight loss, most likely related to the switch from a previous antipsychotic 
treatment. Of those patients who had gained > 7% of their body weight in initial phase of 
the CATIE who were then randomly assigned to ziprasidone in the second phase of the 
trial (Stroup et al., 2006), 42% lost more than 7% of their body weight; 20% of those 
randomly assigned to risperidone lost more than 7% of their body weight; and 7% of 
patients randomly assigned to quetiapina lost 7% of their body weight. None of the 
patients who gained >7% of their body weight in the initial phase of the study and were 
then randomly assigned to olanzapine in the subsequent phase lost more than 7% of their 
body weight. In phase 3 (Stroup et al., 2009), participants selected openly from the 
following nine possible treatment regimens: antipsychotic monotherapy with oral 
aripiprazole (ARIP), clozapine (CLOZ), olanzapine (OLAN), perphenazine (PERP), 
quetiapine (QUET), risperidone (RISP), or ziprasidone (ZPR); long-acting injectable 
fluphenazine decanoate (Flu-D); or a combination of any two of these treatments (Comb). 
If the selected treatment was not discontinued because of inadequate efficacy, 
intolerability, or any other reason, patients could continue taking this regimen until the 
completion of 18 months of study treatment. Of the common choices, those who selected 
aripiprazole and ziprasidone had the highest body mass index and the most monthly 
weight loss was associated with aripiprazole and ziprasidone (Graph. 5). 
Clinicians should consider switching antipsychotics when there is a clear relationship 
between antipsychotic exposure and change in healthrisk category (i.e., obesity, diabetes, 
sleep apnea), the patient is about to stop or has stopped antipsychotic use because of weight 
gain, the patient has bulimia or the patient is abusing weight loss drugs due to newly 
developed weight gain on antipsychotic treatment. Current evidence (Weiden, 2007) 
indicates that switching is an effective strategy primarily in patients whose weight gain is 
attributable to preswitch antipsychotic and in whom long-term monotherapy with a weight-
neutral agent can be maintained. In this population, the effectiveness of switching appears 
to be related to a reversal of the weight-increasing effects of a prior antipsychotic 
medication. 
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Regarding the effect of antipsychotics on the QTc interval, the use of lower doses and 
monotherapy may represent an effective strategy in reducing the risk of QTc lengthening 
(Di Sciascio et al., 2011). 
 
 
Graphic 5. Weight change among the commonly selected treatments in Phase 3 of CATIE 
(Stroup et al., 2009) 
4. Conclusion 
The mortality gap between patients with severe mental illness and the general population 
has substantially widened in recent decades, warranting close attention to the 
cardiovascular health of this patient population. Reasons for the increased prevalence rates 
of CHD risk factors are complex, but include effects of mental illness, poor lifestyle 
behaviors, weight gain, and metabolic abnormalities conferred by psychiatric treatments, 
particularly by SGAs. While the mechanisms for weight gain are still unclear and direct, 
weight-independent mechanisms for at least some SGAs regarding glucose and lipid 
abnormalities have been discussed, it is clear that antipsychotics differ in their risk for 
adverse changes in body weight and metabolic dysregulation (Correll, 2007). 
As individuals with mental illness are more likely to be overweight or obese than the 
general population, weight should be routinely monitored in all patients, especially in those 
receiving treatment with atypical antipsychotic medications associated with weight gain 
(Balf et al., 2008). 
Routine adverse-effect monitoring should be part of any pharmacologic treatment. For 
antipsychotics, this should include baseline assessments of EPS and abnormal involuntary 
movements, sleep duration and quality, daytime sedation, sexual and reproductive 
dysfunction, and risk factors for cardiovascular disease, including unhealthy lifestyle 
(Correll, 2007). 
By using the charts and tables in this article, clinicians will be better informed to educate the 
patient in a variety of interventions that will diminish the potential for medication side 
effects, promote better pharmacologic efficacy from prescribed medications, and improve 
the overall quality of life. 
In conclusion, the management of patients at risk of cardiometabolic disease can be 
complex, but if performed systematically and in conjunction with healthcare professionals 
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who can address the metabolic complications in a complementary fashion, it can provide a 
clinical outcome that will be potentially very beneficial to the individual patient. The 
reintegration of psychiatric care and general somatic services seems to represent one of the 
most important challenges for psychiatric care today. 
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